Superworth

Medline MDLN

Medical - Instruments & Supplies, Healthcare
$34.09
−2.26%
Market cap
$44.8B
PE
n/m
one or more of the four quarters through 2026-06-27 missing
Forward PE
23.2×
Price to sales
n/m
one or more of the four quarters through 2026-06-27 missing
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
n/m
one or more of the four quarters through 2026-06-27 missing
Net margin
n/m
one or more of the four quarters through 2026-06-27 missing
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for MDLN, by quarter
Income statementQ1 FY25Q2 FY25Q1 FY26Q2 FY26
$6.6B$6.9B$7.4B$7.7B
Cost of revenue$4.8B$5B$5.5B$5.5B
Gross profit$1.8B$1.9B$1.8B$2.2B
SG&A$1.1B$1.1B$1.2B$1.3B
$571M$642M$422M$395M
Interest expense$244M$253M$165M$168M
Pre-tax income$338M$359M$291M$235M
$16M$26M$52M$96M
Net incomen/an/a$132M$59M
n/an/a$0.16$0.07
n/an/a825M861M

Net income: Q1 FY26 and Q2 FY26: not printed by the filing, worked out from its own lines.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Estimates

Next earnings report: .

QuarterRevenueRangeEPSRangeAnalysts
Q3 FY26$7.7B$7.7B to $7.7B$0.34$0.32 to $0.3515
Q4 FY26$8.5B$8.4B to $8.5B$0.40$0.37 to $0.4314
Q1 FY27$7.9B$7.8B to $7.9B$0.34$0.34 to $0.356
Q2 FY27$8.3B$8.2B to $8.4B$0.38$0.38 to $0.3811
Q3 FY27$8.3B$8.2B to $8.4B$0.40$0.40 to $0.416
Q4 FY27$9.2B$9.1B to $9.3B$0.46$0.46 to $0.479
Q1 FY28$8.4B$8.3B to $8.5B$0.37$0.36 to $0.3710
Q2 FY28$8.9B$8.8B to $9B$0.42$0.42 to $0.437

Peers

Companies in Medical - Instruments & Supplies nearest Medline's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
MDLNMedline$44.8Bn/mn/a23.2×n/mn/mn/m
BDXBecton, Dickinson and$54.2B60.1×37.5×15.1×2.6×+5%4.5%
RMDResMed$36.5B24.2×37.3×20.8×6.5×+10%26.9%
WSTWest Pharmaceutical Services$27.6B50.2×45.8×42.2×8.3×+12%17.0%
SOLVSolventum$14.5B10.4×10.7×n/m1.7×−1%17.3%
PENPenumbra$12.8B79.7×197×n/m8.5×+18%10.7%
ISRGIntuitive Surgical$159.8B54.7×69.3×37.5×13.8×+20%25.5%
COOCooper Companies$11.6B20.9×40.2×n/m2.7×+5%13.5%
ALGNAlign Technology$11B26.9×43.3×n/m2.7×+4%10.0%
GMEDGlobus Medical$10.9B20.8×37.4×n/m3.5×+20%17.0%
PODDInsulet$10.3B27.9×63.0×n/m3.4×+29%12.3%
Peer median$13.7B27.4×41.8×29.2×3.4×+11%15.2%

Investors who own it

Investors we follow who held Medline at the end of Jun 30, 2026, from their 13F filings.

More on Medline

Each number over time

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .